- | Sotio
SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice – in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner
Radek Spisek, Ph.D. SOTIO discusses SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner Summary: SO-C101 is a IL-15 superagonist being developed for the treatment of advanced solid tumors – currently in an ongoing Phase 1 trial (NCT04234113)
- | CalciMedica
FDA greenlights expansion of COVID-19 study to VCU Medical Center after positive data
When it comes to fighting COVID-19, doctors say your body’s immune response can often time be worse than the symptoms of the disease itself. “Unfortunately, this COVID-19 generates a hyper-immune response. The immune response is actually maladaptive to and that actually causes its own dama
- | Cue Biopharma
Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform
Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in oncology and autoimmunity.
- | Immunomedics
Promise of ADCs in solid tumours: Immunomedics partners with Roche
Roche and Immunomedics have expanded their checkpoint inhibitor-ADC partnership from TNBC to include other solid tumours: UC and NSCLC. What promise does combining ADC Trodelvy and checkpoint inhibitor Tecentriq have in overcoming unmet needs in these cancer types?
- | Anima Biotech
Targeting “Undruggable” Proteins by Selectively Controlling mRNA Translation
Many human diseases are driven by the dysfunction or dysregulation of proteins. However, up to 80% of proteins do not possess binding sites suitable for direct binding of small molecule drugs, making them “undruggable”. To overcome this problem, Anima Biotech has developed their Translation Control Therapeutics platform to identify drugs with the ability to interfere with the production of these “undruggable” proteins, by selectively inhibiting the translation of mRNA.
- | Ziopharm Oncology
Phase 2 Trial Using IL-12 Gene Therapy for Glioblastoma Reaches Recruitment Target
A novel immune-based, gene therapy approach is entering phase 2 trials (ClinicalTrials.gov Identifier: NCT04006119) for glioblastoma multiforme (GBM) after promising preliminary safety and efficacy data. Despite encouraging results in several tumor types such as melanoma, colorectal, and lung, immunotherapies have yet to show any significant benefit in patients with brain tumors. The new technique by Ziopharm hopes to reverse that trend.
- | Arrowhead Pharmaceuticals
First Participants Dosed in Early Clinical Trial of Inhaled Therapy ARO-ENaC
A Phase 1/2 clinical trial assessing Arrowhead Pharmaceuticals‘ investigational inhaled therapy, ARO-ENaC, for the treatment of cystic fibrosis (CF), has dosed its first participants, the company announced.
- | Ansun Biopharma
Russia approves coronavirus vaccine but international community is skeptical
FOX Business’ Ashley Webster on how the international community is reacting to Russia’s announcement of a coronavirus vaccine.
